A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Dose Study to Evaluate the Efficacy and Safety of Oral SKI-O-703, SYK Inhibitor, in Patients With Persistent and Chronic Immune Thrombocytopenia (ITP)
Phase of Trial: Phase II
Latest Information Update: 01 Nov 2019
Price : $35 *
At a glance
- Drugs Cevidoplenib (Primary)
- Indications Idiopathic thrombocytopenic purpura
- Focus Therapeutic Use
- 25 Oct 2019 Status changed from not yet recruiting to recruiting.
- 12 Aug 2019 Status changed from planning to not yet recruiting.
- 07 Jun 2018 New trial record